Related Experiment Video

Updated: Aug 29, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Development of molecular agents for IGF receptor targeting

A J Salisbury1, V M Macaulay

  • 1Cancer Research UK Laboratories, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS UK.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|January 8, 2004
PubMed

Insights

Targeting the type 1 insulin-like growth factor receptor (IGF1R) with molecular agents shows promise for cancer treatment. IGF1R gene silencing inhibits tumor growth, enhances drug sensitivity, and may stimulate anti-tumor immunity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed in many tumors, driving cancer cell proliferation, motility, and survival.
  • Designing specific IGF1R kinase inhibitors is challenging due to structural homology with the insulin receptor.

Purpose of the Study:

  • To review the development of molecular agents targeting IGF1R for cancer therapy.
  • To discuss factors influencing the clinical efficacy and toxicity of IGF1R inhibitors.

Main Methods:

  • Exploration of sequence-specific molecular agents like antisense, triplex, ribozymes, and small interfering RNAs (siRNAs) for IGF1R gene silencing.
  • Review of studies demonstrating IGF1R downregulation effects on tumor growth, metastasis, drug sensitivity, and DNA repair pathways.

Main Results:

  • Small interfering RNAs effectively induce sequence-specific IGF1R gene silencing in mammalian cells.
  • IGF1R downregulation inhibits tumor growth and metastasis, enhances sensitivity to cytotoxic agents and irradiation, and impairs DNA damage response pathways.
  • IGF1R inhibition can also trigger an anti-tumor immune response.

Conclusions:

  • Novel molecular agents targeting IGF1R are nearing clinical availability.
  • Clinical success depends on tumor dependence on IGF signaling, and the efficacy and safety profiles of IGF1R inhibitors.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...